Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Jason Muhitch

Associate Professor of Oncology

Roswell Park Comprehensive Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

About

Jason Muhitch is an Assistant Professor at Roswell Park Cancer Institute in the United States. His research areas include tumor microenvironment reprogramming, immune modulation in cancer therapy, and the effects of radiotherapy on renal cell carcinoma. Recent publications highlight his work on macrophage reprogramming, myeloid-derived suppressor cells, and dynamic changes in T cell repertoires following cancer treatment.

Articles (12)

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Collaborators (1)

Henry Withers

Research Assistant Professor of Oncology

Roswell Park Comprehensive Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jason Muhitch

Research Interests

Explore related searches

About

Articles (12)

Your neighbors matter: Adjacent cancer cells dampen TLS function.

The suppressive function of ILC2 cells is regulated by β2-adrenergic receptor signaling in breast cancer.

TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab.

Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinoma.

Biological and Clinical Insight into the Prevention and Management of Metastatic Renal Cell Carcinoma with a Sarcomatoid Component.

A Bacterial and Ganglioside-based Nanoparticle Initiates Reprogramming of Macrophages and Promotes Antitumor Phenotypes

Tumor and immune remodeling following radiotherapy in human renal cell carcinoma

Mitigating the prevalence and function of myeloid-derived suppressor cells by redirecting myeloid differentiation using a novel immune modulator.

Iron accumulation typifies renal cell carcinoma tumorigenesis but abates with pathological progression, sarcomatoid dedifferentiation, and metastasis.

Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC.

Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer.

Radiation induces dynamic changes to the T cell repertoire in renal cell carcinoma patients

Collaborators (1)

Henry Withers

Make your next move.